董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Neal Walker | 男 | Director | 56 | 17.55万美元 | 未持股 | 2026-03-31 |
| Nancy Miller Rich | 女 | Director | 67 | 17.55万美元 | 未持股 | 2026-03-31 |
| William D. Clark | 男 | Director | 58 | 未披露 | 未持股 | 2026-03-31 |
| William D. Clark | 男 | Director | 56 | 未披露 | 未持股 | 2026-03-31 |
| Richard H. Douglas | 男 | Director and Chair | 73 | 22.59万美元 | 未持股 | 2026-03-31 |
| Martin J. Joyce | 男 | Director | 72 | 19.82万美元 | 未持股 | 2026-03-31 |
| Gary Phillips | 男 | Director | 60 | 19.65万美元 | 未持股 | 2026-03-31 |
| Todd C. Brady | 男 | Director, President and Chief Executive Officer | 54 | 285.85万美元 | 未持股 | 2026-03-31 |
| Ben R. Bronstein | 男 | Director | 76 | 19.27万美元 | 未持股 | 2026-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Alfieri | 男 | Principal Financial Officer and Principal Accounting Officer | 60 | 未披露 | 未持股 | 2026-03-31 |
| Todd C. Brady | 男 | Director, President and Chief Executive Officer | 54 | 285.85万美元 | 未持股 | 2026-03-31 |
董事简历
中英对照 | 中文 | 英文- Neal Walker
-
Neal Walker，曾在Aldeyra Therapeutics， Inc.任职。2013年6月起担任董事会成员。他是上市药物开发公司Aclaris Therapeutics， Inc.的董事会主席，此前曾担任总裁兼首席执行官（直到2022年12月）。他是董事会认证的皮肤科医生和连续企业家，在生物制药行业拥有超过25年的经验。在2012年创立Aclaris Therapeutics， Inc.之前，他曾担任Vicept Therapeutics， Inc.（被Allergan， Inc.收购）的联合创始人、总裁兼首席执行官（2009年至2012年）。他共同创立并领导了许多生命科学公司：Octagon Research Solutions， Inc.，生物制药公司的软件和服务提供商（被Accenture plc收购）；Trigenesis Therapeutics, Inc.，一家专业皮肤科公司，他曾担任首席医疗官（被Dr. Reddy's Laboratories Ltd收购）；和Cutix公司（一家商业皮肤科公司，销售PreSun，这是一个从百时美施贵宝公司收购的防晒霜品牌）。他在强生公司开始了他的制药行业职业生涯。除了Aclaris，他目前也是Zoomi， Inc.和Myota， Inc.的董事会成员。他曾担任Octagon（一家合同研究组织）的董事会成员。他也是Flexible Medical Systems LLC（一家私人持有的医疗设备公司）的顾问委员会成员。他持有The Wharton School of The University of Pennsylvania的工商管理硕士学位，Philadelphia College of Osteopathic Medicine的博士学位，以及Lehigh大学的生物学学士学位。
Neal Walker,is the Chair of the Board of Directors, and since January 2024 the interim Chief Executive Officer at Aclaris Therapeutics, Inc., a publicly traded drug development company, having previously served as President and Chief Executive Officer until December 2022. He is a board-certified dermatologist and serial entrepreneur with over 25 years of experience in the biopharmaceutical industry. Prior to founding Aclaris Therapeutics, Inc. in 2012, he was co-founder, President and CEO of Vicept Therapeutics, Inc. (acquired by Allergan, Inc.) from 2009 to 2012. Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Ltd); and Cutix Inc., a commercial dermatology company that markets PreSun, a sunscreen brand acquired from Bristol-Myers Squibb Co. He began his pharmaceutical industry career at Johnson & Johnson, Inc. In addition to Aclaris, Dr. Walker currently is also on the Board of Directors of Zoomi, Inc, and Myota, Inc. Dr. Walker previously served on the Board of Directors for Octagon, a contract research organization. He is also on the Advisory Board of Flexible Medical Systems LLC, a privately held medical device company. Dr. Walker received his M.B.A. from The Wharton School of the University of Pennsylvania, his D.O. from Philadelphia College of Osteopathic Medicine, and a B.A. in Biology from Lehigh University. - Neal Walker，曾在Aldeyra Therapeutics， Inc.任职。2013年6月起担任董事会成员。他是上市药物开发公司Aclaris Therapeutics， Inc.的董事会主席，此前曾担任总裁兼首席执行官（直到2022年12月）。他是董事会认证的皮肤科医生和连续企业家，在生物制药行业拥有超过25年的经验。在2012年创立Aclaris Therapeutics， Inc.之前，他曾担任Vicept Therapeutics， Inc.（被Allergan， Inc.收购）的联合创始人、总裁兼首席执行官（2009年至2012年）。他共同创立并领导了许多生命科学公司：Octagon Research Solutions， Inc.，生物制药公司的软件和服务提供商（被Accenture plc收购）；Trigenesis Therapeutics, Inc.，一家专业皮肤科公司，他曾担任首席医疗官（被Dr. Reddy's Laboratories Ltd收购）；和Cutix公司（一家商业皮肤科公司，销售PreSun，这是一个从百时美施贵宝公司收购的防晒霜品牌）。他在强生公司开始了他的制药行业职业生涯。除了Aclaris，他目前也是Zoomi， Inc.和Myota， Inc.的董事会成员。他曾担任Octagon（一家合同研究组织）的董事会成员。他也是Flexible Medical Systems LLC（一家私人持有的医疗设备公司）的顾问委员会成员。他持有The Wharton School of The University of Pennsylvania的工商管理硕士学位，Philadelphia College of Osteopathic Medicine的博士学位，以及Lehigh大学的生物学学士学位。
- Neal Walker,is the Chair of the Board of Directors, and since January 2024 the interim Chief Executive Officer at Aclaris Therapeutics, Inc., a publicly traded drug development company, having previously served as President and Chief Executive Officer until December 2022. He is a board-certified dermatologist and serial entrepreneur with over 25 years of experience in the biopharmaceutical industry. Prior to founding Aclaris Therapeutics, Inc. in 2012, he was co-founder, President and CEO of Vicept Therapeutics, Inc. (acquired by Allergan, Inc.) from 2009 to 2012. Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Ltd); and Cutix Inc., a commercial dermatology company that markets PreSun, a sunscreen brand acquired from Bristol-Myers Squibb Co. He began his pharmaceutical industry career at Johnson & Johnson, Inc. In addition to Aclaris, Dr. Walker currently is also on the Board of Directors of Zoomi, Inc, and Myota, Inc. Dr. Walker previously served on the Board of Directors for Octagon, a contract research organization. He is also on the Advisory Board of Flexible Medical Systems LLC, a privately held medical device company. Dr. Walker received his M.B.A. from The Wharton School of the University of Pennsylvania, his D.O. from Philadelphia College of Osteopathic Medicine, and a B.A. in Biology from Lehigh University.
- Nancy Miller Rich
-
Nancy Miller Rich自2020年11月以来一直担任我们的董事会成员。她自2017年9月起担任多家制药和生物技术公司的顾问和顾问。此前，米勒-里奇曾在默克制药公司担任过多个领导职务，在两家公司合并之前，她曾在Schering-PloughCorporation担任过多个领导职务，包括最近担任高级副总裁，全球人类健康业务开发与许可部门的职务，2013年11月至2017年9月提供战略和商业支持，2007年1月至2013年11月担任集团Vice President，Consumer Care Global New Ventures和战略商业开发。1990年加入Schering-Plough之前，Miller-Rich在Sandoz Pharmaceuticals和Sterling Drug，Inc.担任多个商业和营销职位。Miller-Rich女士曾担任多家上市生物技术公司的董事会成员，例如自2018年4月以来担任InterceptPharmaceuticals，Inc.董事，自2020年1月以来担任AldeyraTherapeutics，Inc.董事，自2020年10月以来担任KadmonHoldings，Inc.董事。她于1981年获得纽约伊萨卡学院（Ithaca College）的工商管理营销本科学位。
Nancy Miller Rich,worked for Schering-Plough Corporation, where she was Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from 2013 to 2017 and Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from 2007 to 2013. Prior to joining Schering-Plough in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. She is a director of 4D Molecular Therapeutics, Inc., and previously served as a director of Intercept Pharmaceuticals, Inc. and Kadmon Holdings. Ms. Miller-Rich also serves as a board member of a number of private and not-for-profit entities. Ms. Miller-Rich received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York. - Nancy Miller Rich自2020年11月以来一直担任我们的董事会成员。她自2017年9月起担任多家制药和生物技术公司的顾问和顾问。此前，米勒-里奇曾在默克制药公司担任过多个领导职务，在两家公司合并之前，她曾在Schering-PloughCorporation担任过多个领导职务，包括最近担任高级副总裁，全球人类健康业务开发与许可部门的职务，2013年11月至2017年9月提供战略和商业支持，2007年1月至2013年11月担任集团Vice President，Consumer Care Global New Ventures和战略商业开发。1990年加入Schering-Plough之前，Miller-Rich在Sandoz Pharmaceuticals和Sterling Drug，Inc.担任多个商业和营销职位。Miller-Rich女士曾担任多家上市生物技术公司的董事会成员，例如自2018年4月以来担任InterceptPharmaceuticals，Inc.董事，自2020年1月以来担任AldeyraTherapeutics，Inc.董事，自2020年10月以来担任KadmonHoldings，Inc.董事。她于1981年获得纽约伊萨卡学院（Ithaca College）的工商管理营销本科学位。
- Nancy Miller Rich,worked for Schering-Plough Corporation, where she was Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from 2013 to 2017 and Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from 2007 to 2013. Prior to joining Schering-Plough in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. She is a director of 4D Molecular Therapeutics, Inc., and previously served as a director of Intercept Pharmaceuticals, Inc. and Kadmon Holdings. Ms. Miller-Rich also serves as a board member of a number of private and not-for-profit entities. Ms. Miller-Rich received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York.
- William D. Clark
-
William D. Clark于2021年8月被任命为我们的董事会成员，目前担任审计委员会，提名和公司治理委员会成员。Clark先生拥有超过30年的生物技术和制药经验，专注于业务开发、商业化、战略规划和综合管理。2011年以来，他担任纳斯达克上市的生物制药公司Genocea Biosciences, Inc.“；Genocea”；的总裁兼首席执行官。在这个职位上，除了其他成就外，他成功地执行了Genocea从传染病到免疫肿瘤学的战略转型。加入Genocea之前，他曾担任Vanda Pharmaceuticals Inc.“；Vanda”；的首席商务官，这是一家他于2004年联合创立的公司。在那里，他在完成公司2006年在纳斯达克的首次公开发行和2009年与Novartis Pharma AG的授权交易中发挥了核心作用，Vanda从该交易中获得了2亿美元的预付款，以及总计2.65亿美元的未来里程碑付款。此前，他曾担任Care Capital公司（投资生物制药公司的风险投资公司）的负责人。职业生涯早期，他曾任职SmithKline Beecham Corporation（现为GlaxoSmithKline plc的一部分）10年，担任多种业务开发职务。Clark先生拥有宾夕法尼亚大学沃顿商学院的工商管理硕士学位和哈佛大学的文学学士学位。
William D. Clark,was appointed as a member of Ibio, Inc. Board of Directors in August 2021 and has served as Chairperson of the Board since November 1, 2022. He also currently serves on the Audit Committee and Nominating and Corporate Governance Committee. Mr. Clark has more than 30 years of biotechnology and pharmaceutical experience, with a focus on business development, commercialization, strategic planning, and general management. Currently, Mr. Clark serves as President and CEO of Vibrant Biomedicines, Inc. From 2011 until 2022, he served as the President and Chief Executive Officer of a publicly traded biopharmaceutical company, Genocea Biosciences, Inc. ("Genocea"). In that role, among other accomplishments, he executed Genocea's successful strategic pivot from infectious disease to immuno-oncology. Prior to joining Genocea, Mr. Clark was Chief Business Officer at Vanda Pharmaceuticals Inc. ("Vanda"), a company he co-founded in 2004. There, he played central roles in completing the company's 2006 initial public offering and its 2009 out-licensing deal with Novartis Pharma AG, from which Vanda received an upfront payment of $200 million, plus contingent additional future milestone payments totaling up to $265 million. Previously, he was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies. Earlier in his career, he spent 10 years at SmithKline Beecham Corporation (now part of GlaxoSmithKline plc) in a variety of business development roles. Mr. Clark holds an MBA from The Wharton School at the University of Pennsylvania and a BA from Harvard University. - William D. Clark于2021年8月被任命为我们的董事会成员，目前担任审计委员会，提名和公司治理委员会成员。Clark先生拥有超过30年的生物技术和制药经验，专注于业务开发、商业化、战略规划和综合管理。2011年以来，他担任纳斯达克上市的生物制药公司Genocea Biosciences, Inc.“；Genocea”；的总裁兼首席执行官。在这个职位上，除了其他成就外，他成功地执行了Genocea从传染病到免疫肿瘤学的战略转型。加入Genocea之前，他曾担任Vanda Pharmaceuticals Inc.“；Vanda”；的首席商务官，这是一家他于2004年联合创立的公司。在那里，他在完成公司2006年在纳斯达克的首次公开发行和2009年与Novartis Pharma AG的授权交易中发挥了核心作用，Vanda从该交易中获得了2亿美元的预付款，以及总计2.65亿美元的未来里程碑付款。此前，他曾担任Care Capital公司（投资生物制药公司的风险投资公司）的负责人。职业生涯早期，他曾任职SmithKline Beecham Corporation（现为GlaxoSmithKline plc的一部分）10年，担任多种业务开发职务。Clark先生拥有宾夕法尼亚大学沃顿商学院的工商管理硕士学位和哈佛大学的文学学士学位。
- William D. Clark,was appointed as a member of Ibio, Inc. Board of Directors in August 2021 and has served as Chairperson of the Board since November 1, 2022. He also currently serves on the Audit Committee and Nominating and Corporate Governance Committee. Mr. Clark has more than 30 years of biotechnology and pharmaceutical experience, with a focus on business development, commercialization, strategic planning, and general management. Currently, Mr. Clark serves as President and CEO of Vibrant Biomedicines, Inc. From 2011 until 2022, he served as the President and Chief Executive Officer of a publicly traded biopharmaceutical company, Genocea Biosciences, Inc. ("Genocea"). In that role, among other accomplishments, he executed Genocea's successful strategic pivot from infectious disease to immuno-oncology. Prior to joining Genocea, Mr. Clark was Chief Business Officer at Vanda Pharmaceuticals Inc. ("Vanda"), a company he co-founded in 2004. There, he played central roles in completing the company's 2006 initial public offering and its 2009 out-licensing deal with Novartis Pharma AG, from which Vanda received an upfront payment of $200 million, plus contingent additional future milestone payments totaling up to $265 million. Previously, he was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies. Earlier in his career, he spent 10 years at SmithKline Beecham Corporation (now part of GlaxoSmithKline plc) in a variety of business development roles. Mr. Clark holds an MBA from The Wharton School at the University of Pennsylvania and a BA from Harvard University.
- William D. Clark
-
William D. Clark，曾任Vanda Pharmaceuticals Inc.（万达）的首席商务官，该公司是他于2004年与他人共同创立的一家上市生物技术公司。此前，他是Care Capital，LLC的负责人，该公司是一家专注于生物制药公司投资的风险投资公司。在他职业生涯的早期，他在史克比彻姆公司（现为葛兰素史克公司的一部分）工作了10年，担任过各种管理职务。克拉克先生目前担任iBio Inc.的董事和董事会主席，iBio Inc.是一家上市的生物技术公司。克拉克先生拥有宾夕法尼亚大学沃顿商学院的MBA学位和哈佛大学的学士学位。
William D. Clark,was Chief Business Officer at Vanda Pharmaceuticals Inc. (Vanda), a publicly traded biotechnology company he co-founded in 2004. Previously, he was a Principal at Care Capital, LLC, a venture capital firm focused on investments in biopharmaceutical companies. Earlier in his career, he spent 10 years at SmithKline Beecham Corporation (now part of GlaxoSmithKline plc) in a variety of managerial roles. Mr. Clark currently serves as a director and chairman of the board of iBio Inc., a publicly-traded biotech company. Mr. Clark holds an MBA from The Wharton School at the University of Pennsylvania and a BA from Harvard University. - William D. Clark，曾任Vanda Pharmaceuticals Inc.（万达）的首席商务官，该公司是他于2004年与他人共同创立的一家上市生物技术公司。此前，他是Care Capital，LLC的负责人，该公司是一家专注于生物制药公司投资的风险投资公司。在他职业生涯的早期，他在史克比彻姆公司（现为葛兰素史克公司的一部分）工作了10年，担任过各种管理职务。克拉克先生目前担任iBio Inc.的董事和董事会主席，iBio Inc.是一家上市的生物技术公司。克拉克先生拥有宾夕法尼亚大学沃顿商学院的MBA学位和哈佛大学的学士学位。
- William D. Clark,was Chief Business Officer at Vanda Pharmaceuticals Inc. (Vanda), a publicly traded biotechnology company he co-founded in 2004. Previously, he was a Principal at Care Capital, LLC, a venture capital firm focused on investments in biopharmaceutical companies. Earlier in his career, he spent 10 years at SmithKline Beecham Corporation (now part of GlaxoSmithKline plc) in a variety of managerial roles. Mr. Clark currently serves as a director and chairman of the board of iBio Inc., a publicly-traded biotech company. Mr. Clark holds an MBA from The Wharton School at the University of Pennsylvania and a BA from Harvard University.
- Richard H. Douglas
-
Richard H. Douglas，曾在Aldeyra Therapeutics， Inc.任职。自2016年9月起担任董事会成员。Douglas博士曾担任Genzyme Corporation的高级副总裁，负责企业发展。从1989年到2011年，他领导Genzyme Corporation的企业发展团队，并参与了许多收购、许可、融资、合资企业和战略联盟。从1982年到1989年与Genzyme公司（现为Sanofi Genzyme）合并，Douglas博士担任Integrated Genetics公司的科学和企业发展能力。目前，他是Novavax， Inc.（上市的临床阶段疫苗公司）的董事会成员；MaxCyte, Inc.，一家公开交易的仪器和免疫治疗公司；以及密歇根大学技术转移国家顾问委员会。他持有Michigan大学的化学学士学位和California大学， Berkeley的生物化学博士学位，他是the California Institute of Technology的Leroy Hood实验室的博士后研究员。
Richard H. Douglas,was formerly Senior Vice President, Corporat Development of Genzyme Corporation. From 1989 to 2011, he led the Corporate Development team at Genzyme, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until the merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the Board of Directors of Novavax, Inc., a publicly-traded commercial vaccine company; chairs the Board of Directors of MaxCyte, Inc., a publicly traded instrument company; and is on the University of Michigan Innovation Partnerships National Advisory Board. Dr. Douglas is also an advisor to Red Sky Partners LLC. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in the laboratory of Leroy Hood at the California Institute of Technology. - Richard H. Douglas，曾在Aldeyra Therapeutics， Inc.任职。自2016年9月起担任董事会成员。Douglas博士曾担任Genzyme Corporation的高级副总裁，负责企业发展。从1989年到2011年，他领导Genzyme Corporation的企业发展团队，并参与了许多收购、许可、融资、合资企业和战略联盟。从1982年到1989年与Genzyme公司（现为Sanofi Genzyme）合并，Douglas博士担任Integrated Genetics公司的科学和企业发展能力。目前，他是Novavax， Inc.（上市的临床阶段疫苗公司）的董事会成员；MaxCyte, Inc.，一家公开交易的仪器和免疫治疗公司；以及密歇根大学技术转移国家顾问委员会。他持有Michigan大学的化学学士学位和California大学， Berkeley的生物化学博士学位，他是the California Institute of Technology的Leroy Hood实验室的博士后研究员。
- Richard H. Douglas,was formerly Senior Vice President, Corporat Development of Genzyme Corporation. From 1989 to 2011, he led the Corporate Development team at Genzyme, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until the merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the Board of Directors of Novavax, Inc., a publicly-traded commercial vaccine company; chairs the Board of Directors of MaxCyte, Inc., a publicly traded instrument company; and is on the University of Michigan Innovation Partnerships National Advisory Board. Dr. Douglas is also an advisor to Red Sky Partners LLC. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in the laboratory of Leroy Hood at the California Institute of Technology.
- Martin J. Joyce
-
Martin J. Joyce自从2013年10月起担任董事会成员。Joyce先生的专业背景包括公共和私人领导角色，医疗设备、生物技术和制药公司，在初创阶段年收入超过5亿美元。他拥有公共股本融资、业务发展、SEC报告、战略规划、合并、收购、投资者关系和生物技术操作等方面的经验。2012年起，Joyce先生担任生命科学产业顾问，负责协助生物技术和制药公司的策略规划、筹集资金以及运营。2011年3月至2012年7月，Joyce先生是Lucid公司的首席财务官，该公司是一家早期皮肤癌诊断公司。在此之前，2006年1月至2010年9月，他是BioSphere医疗公司的执行副总裁和首席财务官。2001年1月至2004年9月，Joyce是Stratex集团有限责任公司的管理合伙人，生物制药早期企业行政服务供应商和风险投资者。1996年至2001年1月，Joyce是生物科技Serono公司北美地区的首席财务官。1987年至1996年，Joyce在Serono公司担任了包括金融、销售营销及制造在内的多个职务。最初，他受雇于一家高科技生物科学公司——Millipore Corporation。Joyce在东北大学获得金融学士学位，在马萨诸塞州波士顿的萨福克大学获得MBA学位。
Martin J. Joyce,served as Executive Vice President and Chief Financial Officer of BioSphere Medical from January 2006 through September 2010 and as Chief Financial Officer and Vice President from September 2004 to January 2006. From January 2001 to September 2004, Mr. Joyce served as Managing Partner of Stratex Group LLC, a provider of biopharmaceutical executive services to early-stage companies and venture investors. From 1996 to January 2001, Mr. Joyce was North American Chief Financial Officer for Serono Inc. a biotechnology company. From April 1987 to 1996, Mr. Joyce held a variety of senior level positions within Serono in finance, sales, marketing and manufacturing. Mr. Joyce was previously employed at Millipore Corporation, a high technology bioscience company. Mr. Joyce received a B.S. in finance from Northeastern University and a M.B.A. from Suffolk University, Boston, Massachusetts. - Martin J. Joyce自从2013年10月起担任董事会成员。Joyce先生的专业背景包括公共和私人领导角色，医疗设备、生物技术和制药公司，在初创阶段年收入超过5亿美元。他拥有公共股本融资、业务发展、SEC报告、战略规划、合并、收购、投资者关系和生物技术操作等方面的经验。2012年起，Joyce先生担任生命科学产业顾问，负责协助生物技术和制药公司的策略规划、筹集资金以及运营。2011年3月至2012年7月，Joyce先生是Lucid公司的首席财务官，该公司是一家早期皮肤癌诊断公司。在此之前，2006年1月至2010年9月，他是BioSphere医疗公司的执行副总裁和首席财务官。2001年1月至2004年9月，Joyce是Stratex集团有限责任公司的管理合伙人，生物制药早期企业行政服务供应商和风险投资者。1996年至2001年1月，Joyce是生物科技Serono公司北美地区的首席财务官。1987年至1996年，Joyce在Serono公司担任了包括金融、销售营销及制造在内的多个职务。最初，他受雇于一家高科技生物科学公司——Millipore Corporation。Joyce在东北大学获得金融学士学位，在马萨诸塞州波士顿的萨福克大学获得MBA学位。
- Martin J. Joyce,served as Executive Vice President and Chief Financial Officer of BioSphere Medical from January 2006 through September 2010 and as Chief Financial Officer and Vice President from September 2004 to January 2006. From January 2001 to September 2004, Mr. Joyce served as Managing Partner of Stratex Group LLC, a provider of biopharmaceutical executive services to early-stage companies and venture investors. From 1996 to January 2001, Mr. Joyce was North American Chief Financial Officer for Serono Inc. a biotechnology company. From April 1987 to 1996, Mr. Joyce held a variety of senior level positions within Serono in finance, sales, marketing and manufacturing. Mr. Joyce was previously employed at Millipore Corporation, a high technology bioscience company. Mr. Joyce received a B.S. in finance from Northeastern University and a M.B.A. from Suffolk University, Boston, Massachusetts.
- Gary Phillips
-
Gary Phillips，曾担任Aldeyra Therapeutics, Inc.的成员。2009年5月起担任董事会成员。他曾担任Anaveon AG的首席商务官（2022年5月以来）。在此之前，他于2018年至2022年担任OrphoMed, Inc.的总裁兼首席执行官，并于2013年至2018年担任Mallinckrodt Pharmaceuticals plc的执行副总裁兼首席战略官。此前，他曾担任Bausch & Lomb公司的美国外科和制药总裁以及全球制药主管。此外，他曾担任Geneva世界经济论坛的全球卫生主管，并担任Reckitt Benckiser Pharmaceuticals, Inc.（现为独立）的总裁。他还曾在Merck KGaA、Novartis和Wyeth（现为辉瑞公司）担任高管职务。他曾是Towers Perrin（现为Willis Towers Watson）的医疗保健战略管理顾问，也是美国海军的医务官员，并以中尉指挥官的身份光荣退役。他在University of Pennsylvania接受教育，在那里他获得了医学院的医学博士学位（Alpha Omega Alpha），Wharton商学院的工商管理硕士学位，以及艺术与科学学院的生物化学学士学位（优等生，Phi Beta Kappa）。他在Naval Medical Center San Diego完成了研究生医学教育，并持有有效的医疗执照。
Gary Phillips,has served as Chief Business Officer of Anaveon AG since May 2022. Dr. Phillips currently serves as the Chairman of the supervisory board of Nanobiotix SA. Prior to that, he was President & CEO of OrphoMed, Inc. from 2018 to 2022 and Executive Vice President & Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc from 2013 to 2018. Previously, Dr. Phillips held the dual roles of president, U.S. surgical and pharmaceuticals, and global head of pharmaceuticals at Bausch & Lomb. Additionally, he has served as the head of global health at the World Economic Forum in Geneva and was president of Reckitt Benckiser Pharmaceuticals, Inc. (now Indivior). He has also held executive roles at Merck KGaA, Novartis, and Wyeth (now Pfizer). He was a healthcare strategy managing consultant at Towers Perrin (now Willis Towers Watson) and a medical officer with the United States Navy, from which he was honorably discharged as a lieutenant commander. Dr. Phillips was educated at the University of Pennsylvania, where he received an M.D. (Alpha Omega Alpha) from the School of Medicine, an M.B.A. from the Wharton School, and B.A. (summa cum laude, Phi Beta Kappa) in biochemistry from the College of Arts and Sciences. He completed postgraduate medical education at Naval Medical Center San Diego and maintains an active medical license. - Gary Phillips，曾担任Aldeyra Therapeutics, Inc.的成员。2009年5月起担任董事会成员。他曾担任Anaveon AG的首席商务官（2022年5月以来）。在此之前，他于2018年至2022年担任OrphoMed, Inc.的总裁兼首席执行官，并于2013年至2018年担任Mallinckrodt Pharmaceuticals plc的执行副总裁兼首席战略官。此前，他曾担任Bausch & Lomb公司的美国外科和制药总裁以及全球制药主管。此外，他曾担任Geneva世界经济论坛的全球卫生主管，并担任Reckitt Benckiser Pharmaceuticals, Inc.（现为独立）的总裁。他还曾在Merck KGaA、Novartis和Wyeth（现为辉瑞公司）担任高管职务。他曾是Towers Perrin（现为Willis Towers Watson）的医疗保健战略管理顾问，也是美国海军的医务官员，并以中尉指挥官的身份光荣退役。他在University of Pennsylvania接受教育，在那里他获得了医学院的医学博士学位（Alpha Omega Alpha），Wharton商学院的工商管理硕士学位，以及艺术与科学学院的生物化学学士学位（优等生，Phi Beta Kappa）。他在Naval Medical Center San Diego完成了研究生医学教育，并持有有效的医疗执照。
- Gary Phillips,has served as Chief Business Officer of Anaveon AG since May 2022. Dr. Phillips currently serves as the Chairman of the supervisory board of Nanobiotix SA. Prior to that, he was President & CEO of OrphoMed, Inc. from 2018 to 2022 and Executive Vice President & Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc from 2013 to 2018. Previously, Dr. Phillips held the dual roles of president, U.S. surgical and pharmaceuticals, and global head of pharmaceuticals at Bausch & Lomb. Additionally, he has served as the head of global health at the World Economic Forum in Geneva and was president of Reckitt Benckiser Pharmaceuticals, Inc. (now Indivior). He has also held executive roles at Merck KGaA, Novartis, and Wyeth (now Pfizer). He was a healthcare strategy managing consultant at Towers Perrin (now Willis Towers Watson) and a medical officer with the United States Navy, from which he was honorably discharged as a lieutenant commander. Dr. Phillips was educated at the University of Pennsylvania, where he received an M.D. (Alpha Omega Alpha) from the School of Medicine, an M.B.A. from the Wharton School, and B.A. (summa cum laude, Phi Beta Kappa) in biochemistry from the College of Arts and Sciences. He completed postgraduate medical education at Naval Medical Center San Diego and maintains an active medical license.
- Todd C. Brady
-
Todd C. Brady自2012年1月起担任Aldeyra Therapeutics，Inc.总裁兼首席执行官，自2005年起成为Aldeyla Therapeunics，Inc.董事会成员。加入Aldeyra之前，他曾担任Domain Associates, LLC（一家领先的医疗风险投资公司）的常驻企业家，从2004年到2013年担任负责人。他目前担任Evoke Pharma, Inc.（一家公开交易的医疗保健公司）的董事会成员。他持有Duke University研究生院的病理学博士学位，Duke University医学院的医学博士学位，以及Dartmouth College的哲学和心理学学士学位。
Todd C. Brady,served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the Board of Directors of Evoke Pharma, Inc., a publicly traded healthcare company, and served on the Board of Directors of F-star Therapeutics, Inc. until March 2023. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, an M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology. - Todd C. Brady自2012年1月起担任Aldeyra Therapeutics，Inc.总裁兼首席执行官，自2005年起成为Aldeyla Therapeunics，Inc.董事会成员。加入Aldeyra之前，他曾担任Domain Associates, LLC（一家领先的医疗风险投资公司）的常驻企业家，从2004年到2013年担任负责人。他目前担任Evoke Pharma, Inc.（一家公开交易的医疗保健公司）的董事会成员。他持有Duke University研究生院的病理学博士学位，Duke University医学院的医学博士学位，以及Dartmouth College的哲学和心理学学士学位。
- Todd C. Brady,served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the Board of Directors of Evoke Pharma, Inc., a publicly traded healthcare company, and served on the Board of Directors of F-star Therapeutics, Inc. until March 2023. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, an M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.
- Ben R. Bronstein
-
Ben R. Bronstein，2016年至2017年在Sentien Biotechnologies，Inc.担任临时首席医疗官。2017年至2018年，Bronstein博士在Aclaris Therapeutics担任临床开发执行副总裁。此前，他曾担任Stealth BioTherapeutics，Inc.的首席医疗官、哈佛医学院WYSS生物启发工程研究所的访问学者、Access BridgeGap Ventures的高级副总裁。此前，Bronstein博士曾在多家风险投资支持的生命科学公司创立或担任高级管理职务，包括：Neuron Systems，Inc.（现为Aldeyra Therapeutics, Inc.）；BioSurface Technology，Inc.（已被Genzyme，Inc.收购）；Peptimmune，Inc.（已被Genzyme，Inc.收购）；以及Vidus Ocular，Inc.（已被OPKO保健收购）。Bronstein博士是一名获得委员会认证的病理学家和皮肤病理学家，发表了20多篇文章。布朗斯坦博士的职业生涯始于麻省总医院的工作人员和哈佛医学院的教职员工。直到2024年1月，Bronstein博士一直担任克利夫兰诊断公司董事会的非执行主席。Bronstein博士获得了波士顿大学的医学博士和工商管理硕士学位。
Ben R. Bronstein,served as the interim Chief Medical Officer at Sentien Biotechnologies, Inc. from 2016 to 2017. From 2017 to 2018, Dr. Bronstein served as Executive Vice President, Clinical Development at Aclaris Therapeutics. Previously, he served as Chief Medical Officer of Stealth BioTherapeutics, Inc., as a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School, and Senior Vice President of Access BridgeGap Ventures. Earlier, Dr. Bronstein founded or held senior management positions at several venture-backed life science companies including: Neuron Systems, Inc. (now Aldeyra Therapeutics, Inc.); BioSurface Technology, Inc. (acquired by Genzyme, Inc.); Peptimmune, Inc., (acquired by Genzyme, Inc.); and Vidus Ocular, Inc. (acquired by OPKO Health). Dr. Bronstein is a board-certified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. Until January 2024, Dr. Bronstein served as the non-executive chair of the Board of Directors of Cleveland Diagnostics, Inc. Dr. Bronstein received his M.D. and M.B.A. from Boston University. - Ben R. Bronstein，2016年至2017年在Sentien Biotechnologies，Inc.担任临时首席医疗官。2017年至2018年，Bronstein博士在Aclaris Therapeutics担任临床开发执行副总裁。此前，他曾担任Stealth BioTherapeutics，Inc.的首席医疗官、哈佛医学院WYSS生物启发工程研究所的访问学者、Access BridgeGap Ventures的高级副总裁。此前，Bronstein博士曾在多家风险投资支持的生命科学公司创立或担任高级管理职务，包括：Neuron Systems，Inc.（现为Aldeyra Therapeutics, Inc.）；BioSurface Technology，Inc.（已被Genzyme，Inc.收购）；Peptimmune，Inc.（已被Genzyme，Inc.收购）；以及Vidus Ocular，Inc.（已被OPKO保健收购）。Bronstein博士是一名获得委员会认证的病理学家和皮肤病理学家，发表了20多篇文章。布朗斯坦博士的职业生涯始于麻省总医院的工作人员和哈佛医学院的教职员工。直到2024年1月，Bronstein博士一直担任克利夫兰诊断公司董事会的非执行主席。Bronstein博士获得了波士顿大学的医学博士和工商管理硕士学位。
- Ben R. Bronstein,served as the interim Chief Medical Officer at Sentien Biotechnologies, Inc. from 2016 to 2017. From 2017 to 2018, Dr. Bronstein served as Executive Vice President, Clinical Development at Aclaris Therapeutics. Previously, he served as Chief Medical Officer of Stealth BioTherapeutics, Inc., as a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School, and Senior Vice President of Access BridgeGap Ventures. Earlier, Dr. Bronstein founded or held senior management positions at several venture-backed life science companies including: Neuron Systems, Inc. (now Aldeyra Therapeutics, Inc.); BioSurface Technology, Inc. (acquired by Genzyme, Inc.); Peptimmune, Inc., (acquired by Genzyme, Inc.); and Vidus Ocular, Inc. (acquired by OPKO Health). Dr. Bronstein is a board-certified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. Until January 2024, Dr. Bronstein served as the non-executive chair of the Board of Directors of Cleveland Diagnostics, Inc. Dr. Bronstein received his M.D. and M.B.A. from Boston University.
高管简历
中英对照 | 中文 | 英文- Michael Alfieri
Michael Alfieri自2019年9月起担任Danforth的顾问，该公司是一家为生命科学公司提供战略和运营财务和会计的提供商，在那里他为公共和私营制药和生物技术公司提供财务咨询服务。在此之前，Alfieri先生于2018年4月至2019年3月期间担任生物制药公司Genocea Biosciences, Inc.的副总裁、财务和首席财务官。在加入Genocea之前，Alfieri先生于2017年1月至2018年4月担任生物制药公司Radius Health, Inc.财务副总裁。在加入Radius之前，Alfieri先生于2014年至2017年担任生物制药公司Merrimack Pharmaceuticals, Inc.的公司控制人。Alfieri先生拥有本特利大学的学士和硕士学位。
Michael Alfieri,has served as a consultant with Danforth, a provider of strategic and operational finance and accounting for life science companies, since September 2019, where he provides financial consulting services to both public and private pharma and biotechnology companies. Prior to then, Mr. Alfieri served as Vice President, Finance and Principal Financial Officer of Genocea Biosciences, Inc., a biopharmaceutical company, from April 2018 through March 2019. Prior to Genocea, Mr. Alfieri served as Vice President, Finance of Radius Health, Inc., a biopharmaceutical company, from January 2017 through April 2018. Prior to Radius, Mr. Alfieri served as Corporate Controller of Merrimack Pharmaceuticals, Inc., a biopharmaceutical company from 2014 to 2017. Mr. Alfieri holds both a B.S. and a M.S. from Bentley University.- Michael Alfieri自2019年9月起担任Danforth的顾问，该公司是一家为生命科学公司提供战略和运营财务和会计的提供商，在那里他为公共和私营制药和生物技术公司提供财务咨询服务。在此之前，Alfieri先生于2018年4月至2019年3月期间担任生物制药公司Genocea Biosciences, Inc.的副总裁、财务和首席财务官。在加入Genocea之前，Alfieri先生于2017年1月至2018年4月担任生物制药公司Radius Health, Inc.财务副总裁。在加入Radius之前，Alfieri先生于2014年至2017年担任生物制药公司Merrimack Pharmaceuticals, Inc.的公司控制人。Alfieri先生拥有本特利大学的学士和硕士学位。
- Michael Alfieri,has served as a consultant with Danforth, a provider of strategic and operational finance and accounting for life science companies, since September 2019, where he provides financial consulting services to both public and private pharma and biotechnology companies. Prior to then, Mr. Alfieri served as Vice President, Finance and Principal Financial Officer of Genocea Biosciences, Inc., a biopharmaceutical company, from April 2018 through March 2019. Prior to Genocea, Mr. Alfieri served as Vice President, Finance of Radius Health, Inc., a biopharmaceutical company, from January 2017 through April 2018. Prior to Radius, Mr. Alfieri served as Corporate Controller of Merrimack Pharmaceuticals, Inc., a biopharmaceutical company from 2014 to 2017. Mr. Alfieri holds both a B.S. and a M.S. from Bentley University.
- Todd C. Brady
Todd C. Brady自2012年1月起担任Aldeyra Therapeutics，Inc.总裁兼首席执行官，自2005年起成为Aldeyla Therapeunics，Inc.董事会成员。加入Aldeyra之前，他曾担任Domain Associates, LLC（一家领先的医疗风险投资公司）的常驻企业家，从2004年到2013年担任负责人。他目前担任Evoke Pharma, Inc.（一家公开交易的医疗保健公司）的董事会成员。他持有Duke University研究生院的病理学博士学位，Duke University医学院的医学博士学位，以及Dartmouth College的哲学和心理学学士学位。
Todd C. Brady,served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the Board of Directors of Evoke Pharma, Inc., a publicly traded healthcare company, and served on the Board of Directors of F-star Therapeutics, Inc. until March 2023. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, an M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.- Todd C. Brady自2012年1月起担任Aldeyra Therapeutics，Inc.总裁兼首席执行官，自2005年起成为Aldeyla Therapeunics，Inc.董事会成员。加入Aldeyra之前，他曾担任Domain Associates, LLC（一家领先的医疗风险投资公司）的常驻企业家，从2004年到2013年担任负责人。他目前担任Evoke Pharma, Inc.（一家公开交易的医疗保健公司）的董事会成员。他持有Duke University研究生院的病理学博士学位，Duke University医学院的医学博士学位，以及Dartmouth College的哲学和心理学学士学位。
- Todd C. Brady,served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the Board of Directors of Evoke Pharma, Inc., a publicly traded healthcare company, and served on the Board of Directors of F-star Therapeutics, Inc. until March 2023. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, an M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.